Clinical trial NCT04738773 - References

Gambling Disorder — RCT for Gambling and Naltrexone, Using Use Eye-tracking Analysis to Predict Treatment Response

Citation(s)

•   Altamirano LJ, Fields HL, D'Esposito M, Boettiger CA
  Interaction between family history of alcoholism and Locus of Control in the opioid regulation of impulsive responding under the influence of alcohol. Alcohol Clin Exp Res. 2011 Nov;35(11):1905-14. doi: 10.1111/j.1530-0277.2011.01535.x. Epub 2011 May 13.
•   Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK
  Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999 Nov;156(11):1758-64.
•   Brevers D, Cleeremans A, Bechara A, Laloyaux C, Kornreich C, Verbanck P, Noël X
  Time course of attentional bias for gambling information in problem gambling. Psychol Addict Behav. 2011 Dec;25(4):675-82. doi: 10.1037/a0024201. Epub 2011 Jun 20.
•   Field M, Mogg K, Bradley BP
  Cognitive bias and drug craving in recreational cannabis users. Drug Alcohol Depend. 2004 Apr 9;74(1):105-11.
•   Field M, Mogg K, Zetteler J, Bradley BP
  Attentional biases for alcohol cues in heavy and light social drinkers: the roles of initial orienting and maintained attention. Psychopharmacology (Berl). 2004 Oct;176(1):88-93. Epub 2004 Apr 8.
•   Galetti AM, Tavares H
  Development and validation of the Gambling Follow-up Scale, Self-Report version: an outcome measure in the treatment of pathological gambling. Braz J Psychiatry. 2017 Jan-Mar;39(1):36-44. doi: 10.1590/1516-4446-2016-1911. Epub 2016 Nov 7.
•   Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV
  Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction. 2014 Aug;109(8):1274-84. doi: 10.1111/add.12557. Epub 2014 May 23. Review.
•   Grant JE, Kim SW, Hartman BK
  A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008 May;69(5):783-9.
•   Grant LD, Bowling AC
  Gambling Attitudes and Beliefs Predict Attentional Bias in Non-problem Gamblers. J Gambl Stud. 2015 Dec;31(4):1487-503. doi: 10.1007/s10899-014-9468-z.
•   Hendershot CS, Wardell JD, Samokhvalov AV, Rehm J
  Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. Addict Biol. 2017 Nov;22(6):1515-1527. doi: 10.1111/adb.12425. Epub 2016 Jul 14.
•   Hodgins DC
  Implications of a brief intervention trial for problem gambling for future outcome research. J Gambl Stud. 2005 Spring;21(1):13-9. Review.
•   Kim SW, Grant JE, Adson DE, Shin YC
  Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001 Jun 1;49(11):914-21.
•   Kim SW, Grant JE
  An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001 Sep;16(5):285-9.
•   Lahti T, Halme JT, Pankakoski M, Sinclair D, Alho H
  Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull. 2010;43(3):35-44.
•   Lole L, Li E, Russell AM, Greer N, Thorne H, Hing N
  Are sports bettors looking at responsible gambling messages? An eye-tracking study on wagering advertisements. J Behav Addict. 2019 Sep 1;8(3):499-507. doi: 10.1556/2006.8.2019.37. Epub 2019 Aug 26.
•   McGrath DS, Meitner A, Sears CR
  The specificity of attentional biases by type of gambling: An eye-tracking study. PLoS One. 2018 Jan 31;13(1):e0190614. doi: 10.1371/journal.pone.0190614. eCollection 2018.
•   Mitchell JM, Tavares VC, Fields HL, D'Esposito M, Boettiger CA
  Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. Neuropsychopharmacology. 2007 Feb;32(2):439-49. Epub 2006 Oct 18.
•   Nestler EJ
  From neurobiology to treatment: progress against addiction. Nat Neurosci. 2002 Nov;5 Suppl:1076-9. Review.
•   O'Brien CP, Volpicelli LA, Volpicelli JR
  Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996 Jan-Feb;13(1):35-9. Review.
•   Robinson TE, Berridge KC
  Addiction. Annu Rev Psychol. 2003;54:25-53. Epub 2002 Jun 10. Review.
•   Robinson TE, Berridge KC
  Incentive-sensitization and addiction. Addiction. 2001 Jan;96(1):103-14. Review.
•   Ruddock HK, Field M, Jones A, Hardman CA
  State and trait influences on attentional bias to food-cues: The role of hunger, expectancy, and self-perceived food addiction. Appetite. 2018 Dec 1;131:139-147. doi: 10.1016/j.appet.2018.08.038. Epub 2018 Aug 29.
•   Schultz W, Dayan P, Montague PR
  A neural substrate of prediction and reward. Science. 1997 Mar 14;275(5306):1593-9. Review.
•   Sinclair JD
  Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001 Jan-Feb;36(1):2-10. Review.
•   Vitaro F, Hartl AC, Brendgen M, Laursen B, Dionne G, Boivin M
  Genetic and environmental influences on gambling and substance use in early adolescence. Behav Genet. 2014 Jul;44(4):347-55. doi: 10.1007/s10519-014-9658-6. Epub 2014 May 14.
•   Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP
  Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992 Nov;49(11):876-80.
•   Wickelgren I
  Getting the brain's attention. Science. 1997 Oct 3;278(5335):35-7.
•   Wilcockson TDW, Pothos EM
  Measuring inhibitory processes for alcohol-related attentional biases: introducing a novel attentional bias measure. Addict Behav. 2015 May;44:88-93. doi: 10.1016/j.addbeh.2014.12.015. Epub 2014 Dec 27.
•   Yau YH, Potenza MN
  Gambling disorder and other behavioral addictions: recognition and treatment. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):134-46. doi: 10.1097/HRP.0000000000000051. Review.

Double Blind 12-week Controlled Experiment With Two Groups of Pathological Gamblers, One Taking Active Drug (Naltrexone) and the Other Receiving Placebo.Patters Patterns of Visual Tracking Will be Acessed on Both Groups Prior and During Tratment in Order to Predict Treatment Response

Details for clinical trial NCT04738773